Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

TriWise Capital

Founders Dajie Tang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 21
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 17
Rounds per year 2.33
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.19
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Biopharma
  • Pharmaceutical
Summary

TriWise Capital appeared to be the VC, which was created in 2015. The company was established in Asia in China. The main office of represented VC is situated in the Shenzhen.

The fund was created by Dajie Tang.

The high activity for fund was in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the TriWise Capital, startups are often financed by Shenzhen Capital Group, ShenZhen GTJA Investment Group, Qianhai Xino. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, ShenZhen GTJA Investment Group, Qianhai Fund of Funds. In the next rounds fund is usually obtained by Sino Biopharmaceutical, Shenzhen Capital Group, Loyal Valley Capital.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Therapeutics, Health Care. Among the various public portfolio startups of the fund, we may underline Akeso Biopharma Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of TriWise Capital:
Typical Co-investors
TriWise Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after TriWise Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alchemy Partners England, London, United Kingdom
CBC Co -
Finn Capital Partners California, San Francisco, United States
Frontier Digital Ventures Kuala Lumpur, Malaysia
Hermes Private Equity England, London, United Kingdom
ING Furman Selz Asset Management New York, New York, United States
Jinggong Hongyuan Beijing, Beijing, China
Kentucky Cabinet For Economic Development -
NeoCarta Ventures California, San Mateo, United States
Newton Fund California, San Francisco, United States
Nomow Incubator Ar Riyad, Riyadh, Saudi Arabia
Onroad Capital China, Guangdong, Shenzhen
Rainmakers California, San Francisco, United States
Rebel Foods India, Maharashtra, Pune
Renault Boulogne-Billancourt, France, Ile-de-France
RSVP Capital Ann Arbor, Michigan, United States
Space Capital New York, New York, United States
Swisscom Bern, Switzerland, Worblaufen
Trust China Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Crystal Egg Bio

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$1M13 Sep 2024 Shenzhen, Guangdong, China

BiyoPharma

26 Apr 2024 -

Baikuirui

23 Apr 2024 Shenzhen, Guangdong, China

Shentuo Biotechnology

Biotechnology
Genetics
Medical
29 Dec 2023 Wuxi Shi, Jiangsu, China

Heranova Lifesciences

Biotechnology
Health Care
Medical
$3M28 Dec 2023 Huangpu, Shanghai, China

Hengsai Biological

Health Care
Medical
$15M27 Nov 2023 -

Conmind Medical

Manufacturing
Medical Device
Neuroscience
$15M21 Aug 2023 Shenzhen, Guangdong, China

Bite Micro

Medical
Medical Device
Therapeutics
21 Jun 2023 Shenzhen, Guangdong, China

Immune-Onc Therapeutics

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
$25M05 Jan 2023 Palo Alto, California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent TriWise Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 21
Average round size 34M
Rounds per year 2.33
Peak activity year 2023
Lead investments 4
Follow on index 0.19
Exits 1
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Crystal Egg Bio

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$1M13 Sep 2024 Shenzhen, Guangdong, China

BiyoPharma

26 Apr 2024 -

Baikuirui

23 Apr 2024 Shenzhen, Guangdong, China

Shentuo Biotechnology

Biotechnology
Genetics
Medical
29 Dec 2023 Wuxi Shi, Jiangsu, China

Heranova Lifesciences

Biotechnology
Health Care
Medical
$3M28 Dec 2023 Huangpu, Shanghai, China

Hengsai Biological

Health Care
Medical
$15M27 Nov 2023 -

Conmind Medical

Manufacturing
Medical Device
Neuroscience
$15M21 Aug 2023 Shenzhen, Guangdong, China

Bite Micro

Medical
Medical Device
Therapeutics
21 Jun 2023 Shenzhen, Guangdong, China

Immune-Onc Therapeutics

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
$25M05 Jan 2023 Palo Alto, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: